Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
OncoSec Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
OncoSec Medical Inc, Medical Devices Deals, 2011 to YTD 2017 10
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
OncoSec Medical Enters into Agreement with Jounce Therapeutics 12
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 13
OncoSec Medical Enters into Research Agreement with University of Washington 14
Licensing Agreements 15
OncoSec Medical Enters Into Licensing Agreement With USF Research Foundation For Electroporation Intellectual Property 15
Inovio Pharma Enters Into Licensing Agreement With OncoSec Medical 16
Equity Offering 17
OncoSec Medical to Raise USD9.3 Million in Private Placement of Shares upon Exercise of Warrants 17
OncoSec Medical Raises USD7 Million in Private Placement of Shares 18
Oncosec Medical Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 20
OncoSec Medical Plans to Raise up to USD8.4 Million in Public Offering of Shares 21
OncoSec Medical Raises USD10 Million in Registered Direct Offering 22
OncoSec Medical Raises USD7.5 Million in Private Placement of Shares 23
OncoSec Medical Raises USD13.6 Million in Private Placement of Shares 24
OncoSec Medical Raises USD16 Million in Private Placement of Shares and Warrants 25
OncoSec Medical Completes Private Placement Of Shares For US$12 Million 26
OncoSec Medical Completes Private Placement Of Common Stock For US$7 Million 27
OncoSec Medical Completes Public Offering Of Units For US$8 Million 28
OncoSec Medical Inc – Key Competitors 29
OncoSec Medical Inc – Key Employees 30
OncoSec Medical Inc – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Oct 25, 2017: OncoSec Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2017 32
Jun 01, 2017: OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2017 34
Mar 16, 2017: OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2017 36
Dec 08, 2016: OncoSec Announces First Quarter Financial Results for Fiscal Year 2017 37
Oct 13, 2016: OncoSec Announces Fourth Quarter and Year End Results for Fiscal Year 2016 38
Jun 09, 2016: OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016 39
Mar 08, 2016: OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2016 and Calendar 2016 Milestones 40
Corporate Communications 41
Nov 07, 2017: OncoSec Appoints Daniel J. O’Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company 41
Sep 07, 2017: OncoSec Appoints Industry Leader Daniel J. O’Connor to its Board of Directors 42
Sep 06, 2016: OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer 43
Apr 15, 2016: OncoSec Announces New Senior Leadership Responsibilities 44
Feb 29, 2016: OncoSec Appoints Sharron Gargosky, PhD, as Head of Clinical Development and Operations 45
Product News 46
10/18/2016: OncoSec to Host Investor & Analyst Day on November 17, 2016 Spotlighting Industry-Leading Intratumoral Immunotherapy Pipeline and Next Generation Research and Device Development 46
04/19/2016: OncoSec Presents Positive Melanoma Clinical Data at American Association for Cancer Research Annual Meeting 2016 47
04/13/2016: OncoSec to Host Webcast and Panel Discussion on New Melanoma Clinical Data 48
Product Approvals 49
Jun 08, 2017: OncoSec Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Unresectable Metastatic Melanoma 49
Feb 27, 2017: OncoSec Granted FDA Fast Track Designation for ImmunoPulse IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab 50
Clinical Trials 51
Apr 03, 2017: OncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting 51
Mar 21, 2017: OncoSec Medical’s Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models 52
Feb 23, 2017: OncoSec Announces Positive Phase II Data Demonstrating Company’s ImmunoPulse IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients 53
Feb 08, 2017: OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February 54
Nov 17, 2016: OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016 55
Nov 11, 2016: OncoSec Presents Positive Interim Response Data at the Society for Immunotherapy of Cancer Annual Meeting 2016 56
Nov 08, 2016: OncoSec Announces Positive Interim Response Data at the Society for Immunotherapy of Cancer Annual Meeting 2016 57
Nov 01, 2016: OncoSec to Present at Scientific and Investment Conferences and to Host Inaugural Investor and Analyst Day in November 58
Oct 13, 2016: OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016 59
Aug 15, 2016: OncoSec Announces Peer-Reviewed Publication of T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Therapy in Melanoma 60
Jun 16, 2016: OncoSec Presents Preliminary Findings from Head and Neck Phase II Clinical Trial at EUROGIN 2016 Conference 61
Jun 06, 2016: OncoSec Collaborators Present Results of Novel T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Monotherapy 62
Mar 02, 2016: OncoSec Completes Patient Enrollment in Phase II Extension Study of ImmunoPulse IL-12 in Melanoma 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
OncoSec Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
OncoSec Medical Inc, Deals By Therapy Area, 2011 to YTD 2017 9
OncoSec Medical Inc, Medical Devices Deals, 2011 to YTD 2017 10
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
OncoSec Medical Enters into Agreement with Jounce Therapeutics 12
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 13
OncoSec Medical Enters into Research Agreement with University of Washington 14
OncoSec Medical Enters Into Licensing Agreement With USF Research Foundation For Electroporation Intellectual Property 15
Inovio Pharma Enters Into Licensing Agreement With OncoSec Medical 16
OncoSec Medical to Raise USD9.3 Million in Private Placement of Shares upon Exercise of Warrants 17
OncoSec Medical Raises USD7 Million in Private Placement of Shares 18
Oncosec Medical Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 20
OncoSec Medical Plans to Raise up to USD8.4 Million in Public Offering of Shares 21
OncoSec Medical Raises USD10 Million in Registered Direct Offering 22
OncoSec Medical Raises USD7.5 Million in Private Placement of Shares 23
OncoSec Medical Raises USD13.6 Million in Private Placement of Shares 24
OncoSec Medical Raises USD16 Million in Private Placement of Shares and Warrants 25
OncoSec Medical Completes Private Placement Of Shares For US$12 Million 26
OncoSec Medical Completes Private Placement Of Common Stock For US$7 Million 27
OncoSec Medical Completes Public Offering Of Units For US$8 Million 28
OncoSec Medical Inc, Key Competitors 29
OncoSec Medical Inc, Key Employees 30